NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 – GENERAL ORGANIZATION
AND BUSINESS
Genufood
Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on
June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in
Singapore, which ceased its operations
on January 9, 2023.
Since its
inception, the Company has always been in the development stage and never generated significant revenues. The Company is currently developing
business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During
the three months ended December 31, 2022, the Company has initiated its electric vehicle charging station business.
The Company
made two investments in Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of Hukui’s Series
C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock
for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and
Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares
of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per
share. The sale of the Hukui Shares closed on November 19, 2021.
On August 1, 2022, the
board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle
supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August
16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry,
including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to
bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral
vehicle-charging infrastructure.
On October 26, 2022,
the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site
Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations
at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share
the revenue generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth
therein.
As of December 31, 2022, the Company has purchased
certain electric vehicle charging equipment. Furthermore, the Company is in the process of obtaining permits to construct the Charging
Stations at the three confirmed sites. As of December 31, 2022, the Company contracted an architectural firm on providing designing and
engineering services for two sites, and working on technical issues for the third site.
As of February 13, 2023, the Company has received
the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also
received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities.
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation
The Company’s
condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United
States of America (“US GAAP”). The accompanying condensed consolidated financial statements reflect all adjustments, consisting
of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for
the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2023. These
condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes
included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022.
Principle of Consolidation
The condensed
consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts
and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities during
the three months ended December 31, 2022 and 2021.
Use of
Estimates
The preparation
of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those
estimates.
GENUFOOD ENERGY ENZYMES
CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Concentrations
of Credit Risk
Financial
instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent
balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains
reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.
Cash
and Cash Equivalents
The Company
considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of December
31, 2022 and September 30, 2022, the Company did not have cash equivalents. The Company’s cash was denominated in United States
Dollars (“USD”) or New Taiwan Dollars (“TWD”) and was placed with banks in the United States of America and Taiwan.
Fair
Value of Financial Instruments
The Company
follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect
to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes
the inputs used in measuring fair value as follows:
|
● |
Level 1 inputs are quoted prices available for identical assets and liabilities in active markets. |
|
|
|
|
● |
Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data. |
|
|
|
|
● |
Level 3 inputs are less observable and reflect our own assumptions. |
The Company’s
financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties.
The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to
their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit
risks arising from these financial instruments.
Foreign
Currency Translation and Transactions
The reporting
and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar
(“SGD”).
For financial
reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated
into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet
date, which was 0.7464 and 0.6970 as of December 31, 2022 and September 30, 2022, respectively. Revenue and expenses are translated using
average exchange rates prevailing during each reporting period. The 0.7214 and 0.7370 average exchange rates
were used to translate revenues and expenses for the three months ended December 31, 2022 and 2021, respectively. Stockholders’
equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of
accumulated other comprehensive loss in stockholders’ deficit.
Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the
accompanying condensed consolidated statements of operations.
GENUFOOD ENERGY ENZYMES
CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Business
Segments
The Company
operates in only one segment.
Net Income (Loss) Per Share
The Company
calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by
dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed
similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would
have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There
were no potential dilutive debt or equity instruments issued and outstanding at any time during the three months ended December 31, 2022
and 2021.
Discounts
on Common Stock
Common stock
issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown
separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.
Stock-Based Compensation
The Company
accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB
ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in
exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.
Income
Taxes
Income taxes
are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax
bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.
The Company
considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not
be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts
of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its
tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable
income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible.
When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future
reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards,
(iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be
reflected within the industry.
GENUFOOD ENERGY ENZYMES
CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The Company
recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position
will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold,
the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50%
likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized
tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new
or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective
tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate
by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.
There were
no current and deferred income tax provision recorded for the three months ended December 31, 2022 and 2021 since the Company is in developing
stage and did not generate any revenues in the two fiscal periods.
Recent
Accounting Pronouncements
The Company
considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s
consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to
have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company
feels may be applicable to the Company are as follows:
In August
2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and
Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments
and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt
and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible
preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the
host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with
embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative,
and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial
premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating
the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.
NOTE
3 – GOING CONCERN
As of December
31, 2022 and September 30, 2022, the Company had an accumulated deficit of $10,128,993 and $9,922,955, respectively. To date, the
Company’s cash flow requirements have been primarily met through proceeds received from sales of Common Stock and investment. These
and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial
statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and
liabilities that may result in the Company not being able to continue as a going concern.
The Company sold the 140,000 Hukui
Shares for $350,000 cash on November 19, 2021. The proceeds have been used for operation expenses. Management is currently seeking
additional funds for the Company’s future operation.
GENUFOOD ENERGY ENZYMES
CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 4 – EQUIPMENT
As
of December 31, 2022 and September 30, 2022, the Company had equipment of $15,005 and $0,
respectively, consisting of equipment to be installed at its electric vehicle charging stations.
NOTE
5 – INVESTMENT
Pursuant
to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui
Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share,
for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15,
2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of
$800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per
share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total
equity with no significant control over or influence on Hukui. The investment is recorded at cost.
On November
17, 2021, the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a
total of $350,000. The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss
of the market value of the shares of $1,050,000 for the year ended September 30, 2021.
NOTE
6 – STOCKHOLDERS’ EQUITY (DEFICIT)
The Company
is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per
share.
Stock
Options
On July
15, 2022, the CEO, David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of December 31,
2022, total options granted was 15,000,000 and none was vested. This option will be subject to a vesting schedule providing
for twenty-five percent (25%) vesting after the first twelve (12) months of employment and monthly vesting as to the remaining seventy-five
percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of the employment commencement date.
These stock options are exercisable over a maximum period of 10 years from the grant date. The weighted average grant date fair
value of options granted during the year ended September 30, 2022 was $0.02.
Compensation
costs associated with the Company’s stock options are recognized, based on the grant-date fair value of these options, over the
requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $75,000 and
$0, respectively, which was included in the general and administrative expenses in the condensed consolidated statements of operations
for the three months ended December 31, 2022 and 2021.
GENUFOOD ENERGY ENZYMES
CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The fair
value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions:
| |
September 30,
2022 | | |
September 30,
2021 | |
Risk-free interest rate | |
| 2.99 | % | |
| – | |
Expected term | |
| 6.08 years | | |
| – | |
Expected volatility | |
| 379.35 | % | |
| – | |
Expected dividend yield | |
| 0 | % | |
| – | |
The following
is a summary of the option activity for the three months ended December 31, 2022:
Options | |
Number of Underlying Shares | | |
Weighted average exercise price | | |
Weighted Average Remaining Contractual Life (years) | | |
Aggregate Intrinsic Value | |
Outstanding at October 1, 2022 | |
| 15,000,000 | | |
$ | 0.01 | | |
| – | | |
$ | – | |
Granted | |
| – | | |
$ | – | | |
| – | | |
$ | – | |
Exercised | |
| – | | |
$ | – | | |
| – | | |
$ | – | |
Forfeited or expired | |
| – | | |
$ | – | | |
| – | | |
$ | – | |
Outstanding at December 31, 2022 | |
| 15,000,000 | | |
$ | 0.01 | | |
| 9.5 | | |
$ | 330,000 | |
Vested and expected to vest as of December 31, 2022 | |
| 15,000,000 | | |
$ | 0.01 | | |
| 9.5 | | |
$ | 330,000 | |
Exercisable at December 31, 2022 | |
| – | | |
$ | – | | |
| – | | |
$ | – | |
As of December
31, 2022, unrecognized total compensation cost associated with these options was $161,712. This expense is expected to be
recognized over a weighted-average period of 3.54 years.
NOTE
7 – RELATED PARTY TRANSACTIONS
Related Parties
Name of related parties |
|
Relationship with the Company |
Yi Lung (Oliver) Lin |
|
Principal shareholder |
Jui Pin (John) Lin |
|
Principal shareholder, Director, Former President and Chief Executive Officer |
Jia Tian (Jeffery) Lin |
|
Former Chief Executive Officer |
Wen-Piao (Jack) Lai |
|
Director, Former President and Chief Executive Officer |
Shao-Cheng (Will) Wang |
|
Chief Financial Officer |
Kuang Ming (James) Tsai |
|
Director |
Nan-Yao (Jake) Chan |
|
Former Director |
Hsin-Ta (Darren) Su |
|
Director, Treasurer |
Hui-Chuan (Sandra) Lin |
|
Director and Secretary, daughter of Jui Pin (John) Lin |
GENUFOOD ENERGY ENZYMES
CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Due
to Related Parties
The Company’s
due to related parties balances are as follows:
| |
December 31, 2022 | | |
September 30, 2022 | |
Kuang Ming (James) Tsai | |
$ | 26,155 | | |
$ | 20,755 | |
Jui Pin (John) Lin | |
| 17,048 | | |
| 8,048 | |
Jia Tian (Jeffery) Lin | |
| 2,500 | | |
| 2,500 | |
Shao-Cheng (Will) Wang | |
| 34,500 | | |
| 27,600 | |
Wen-Piao (Jack) Lai | |
| 24,010 | | |
| 22,210 | |
Hsin-Ta (Darren) Su | |
| 18,271 | | |
| 17,189 | |
Hui-Chuan (Sandra) Lin | |
| 9,929 | | |
| 4,529 | |
Nao-Yao (Jake) Chan | |
| 1,800 | | |
| - | |
Total | |
$ | 134,213 | | |
$ | 102,831 | |
The related
party balances are unsecured, interest-free and due on demand.
NOTE 8 – INCOME TAXES
The Company
has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in
2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income
tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department
of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka
that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established
in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively, and the Singapore subsidiary
has been inactive since 2016.
Internal
Revenue Code (“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471)
and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for
each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate
information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date
of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.
The Company
believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be
charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of
penalties that may be assessed.
During the
fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information
Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September
30, 2020. The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount
of $4,976, for a total of $29,976, which was still pending as of December 31, 2022.
GENUFOOD ENERGY ENZYMES
CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE
9 – COMMITMENTS AND CONTINGENCIES
The Company
terminated its previous virtual office agreement in Los Angeles, California and has established a new virtual office in Arcadia, California.
The new arrangement is on a month-to-month basis at a cost of $200 per month. As of December 31, 2022, the Company had no material
commitments under operating leases.
During the
fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information
Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September
30, 2020 (see Note 8).
NOTE
10 – SUBSEQUENT EVENTS
The Company
has closed GESPL, its Singapore subsidiary, as of January 9, 2023. GESPL does not have any operation.
Management
has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated
financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the
consolidated financial statements.